Last 27 quarters of trend data · Healthcare · Medical - Healthcare Information Services
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
GoodRx Holdings, Inc.'s quarterly P/E stands at 16.6x, down 55.0% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has compressed 68.2% YoY to 3.4x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 31.18 | 16.55 | 42.61 | 330.47 | 34.58 | 36.75 | 58.13 | 54.91 | 97.50 | — | — | — | 9.86 |
| — | -55.0% | -26.7% | +501.9% | -64.5% | — | — | — | +889.1% | — | — | — | — | |
| P/S Ratio | 1.16 | 0.86 | 1.19 | 1.88 | 2.19 | 2.06 | 2.25 | 3.45 | 3.74 | 3.50 | 3.41 | 3.23 | 3.01 |
| — | -58.2% | -47.2% | -45.6% | -41.4% | -41.1% | -34.1% | +6.8% | +24.1% | -0.1% | +30.9% | +25.6% | -5.2% | |
| P/B Ratio | 1.54 | 1.08 | 1.50 | 2.45 | 2.77 | 2.56 | 2.46 | 3.87 | 4.48 | 4.39 | 3.52 | 2.64 | 2.55 |
| — | -58.0% | -39.1% | -36.7% | -38.3% | -41.7% | -30.1% | +46.6% | +75.5% | +40.9% | +49.5% | +8.0% | -14.4% | |
| P/FCF | 5.61 | 15.63 | 7.30 | 6.34 | 14.22 | — | 15.87 | 7.80 | — | 31.51 | 223.73 | 12.48 | 38.36 |
| — | — | -54.0% | -18.7% | — | — | -92.9% | -37.5% | — | -12.0% | +673.9% | -48.3% | +134.7% | |
| EV / EBITDA | 4.17 | 3.44 | 3.93 | 12.09 | 10.78 | 10.81 | 12.60 | 18.56 | 21.60 | 31.58 | 26.86 | — | 15.81 |
| — | -68.2% | -68.8% | -34.9% | -50.1% | -65.8% | -53.1% | — | +36.6% | +30.9% | -1.2% | — | -75.7% | |
| EV / EBIT | 8.23 | — | 7.33 | 29.80 | 16.87 | 17.52 | 20.63 | 34.41 | 30.36 | 49.31 | — | — | 21.43 |
| — | — | -64.5% | -13.4% | -44.4% | -64.5% | — | — | +41.7% | +30.3% | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
GoodRx Holdings, Inc.'s operating margin was 7.2% in Q1 2026, down 4.4 pp QoQ and down 4.3 pp YoY. The trailing four-quarter average of 10.0% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 4.1% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 92.8% | 89.6% | 91.0% | 93.2% | 83.7% | 93.4% | 93.9% | 94.0% | 94.1% | 93.7% | 92.3% | 89.6% | 91.4% |
| — | -4.1% | -3.0% | -0.9% | -11.0% | -0.3% | +1.7% | +4.9% | +3.0% | +3.1% | +1.9% | -1.2% | +0.9% | |
| Operating Margin | 11.0% | 7.2% | 11.6% | 7.5% | 13.6% | 11.5% | 9.2% | 10.5% | 9.9% | 3.7% | -9.3% | -21.3% | 9.7% |
| — | -37.3% | +27.2% | -28.6% | +37.7% | +208.8% | +198.4% | +149.1% | +2.7% | -39.3% | -1085.7% | -153.9% | +557.5% | |
| Net Margin | 3.8% | 5.2% | 2.8% | 0.6% | 6.3% | 5.4% | 3.4% | 6.3% | 3.3% | -0.5% | -13.2% | -21.4% | 31.0% |
| — | -4.3% | -17.9% | -90.9% | +89.5% | +1167.9% | +125.8% | +129.4% | -89.2% | +71.5% | -1128.2% | +4.0% | +4300.7% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 4.5% | 1.6% | 0.9% | 0.2% | 2.0% | 1.6% | 0.9% | 1.8% | 1.0% | -0.1% | -3.1% | -4.3% | 6.8% |
| — | +1.9% | -6.0% | -90.0% | +92.3% | +1206.2% | +130.1% | +141.4% | -84.9% | +63.8% | -1179.9% | +16.6% | +3968.7% | |
| ROA | 2.2% | 0.6% | 0.4% | 0.1% | 1.0% | 0.8% | 0.5% | 0.9% | 0.5% | -0.1% | -1.6% | -2.3% | 3.6% |
| — | -28.3% | -19.1% | -90.2% | +115.0% | +1342.5% | +131.3% | +138.3% | -87.2% | +67.4% | -1171.8% | +14.3% | +4036.8% | |
| ROIC | 10.6% | 2.4% | 2.6% | 1.2% | 2.3% | 2.0% | 1.7% | 1.8% | 1.8% | 0.7% | -1.7% | -3.5% | 1.7% |
| — | +19.5% | +58.8% | -32.9% | +28.3% | +197.3% | +197.1% | +152.5% | +6.6% | -36.8% | -1109.4% | -129.2% | +496.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
GoodRx Holdings, Inc.'s Debt/EBITDA ratio is 1.6x, up from 1.3x last quarter — comfortably within a safe range. The current ratio has weakened 71.8% YoY to 1.47x, tightening the short-term liquidity position. Debt/Equity has declined for 3 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.09 | 0.10 | 0.91 | 0.85 | 0.83 | 0.75 | 0.78 | 1.06 | 1.13 | 0.93 | 0.81 | 0.80 |
| — | -88.5% | -87.1% | +16.1% | -19.4% | -26.5% | -19.6% | -3.1% | +32.4% | +30.1% | +6.1% | -8.9% | -6.8% | |
| Debt / EBITDA | 0.34 | 1.65 | 1.30 | 15.12 | 11.54 | 12.22 | 14.58 | 14.35 | 19.20 | 30.45 | 28.08 | — | 20.17 |
| — | -86.5% | -91.1% | +5.4% | -39.9% | -59.9% | -48.1% | — | -4.8% | +11.6% | -32.4% | — | -73.3% | |
| Current Ratio | 2.61 | 1.47 | 2.61 | 3.11 | 4.21 | 5.23 | 5.32 | 5.48 | 7.32 | 6.29 | 7.12 | 8.23 | 11.14 |
| — | -71.8% | -50.9% | -43.3% | -42.6% | -16.9% | -25.3% | -33.4% | -34.2% | -52.2% | -40.9% | -20.4% | -0.8% | |
| Quick Ratio | 2.61 | 1.47 | 2.61 | 3.11 | 4.21 | 5.23 | 5.32 | 5.48 | 7.32 | 6.29 | 7.12 | 8.23 | 11.14 |
| — | -71.8% | -50.9% | -43.3% | -42.6% | -16.9% | -25.3% | -33.4% | -34.2% | -52.2% | -40.9% | -20.4% | -0.8% | |
| Interest Coverage | 2.33 | 1.43 | 2.36 | 1.72 | 2.82 | 2.57 | 2.00 | 1.66 | 1.80 | 1.02 | -0.66 | -2.17 | 1.86 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 27 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying GDRX stock.
GoodRx Holdings, Inc.'s current P/E is 31.2x. The average P/E over the last 4 quarters is 106.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
GoodRx Holdings, Inc.'s current operating margin is 11.0%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking GoodRx Holdings, Inc.'s business trajectory between earnings reports.